Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2026)

Indivior Pharmaceuticals has reported Non-Current Assets for 6 years, with the latest figure at $508.0 million in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 1.4% year-over-year to $508.0 million in Q2 2026; TTM through Jun 2026 was $2.1 billion, a 4.94% increase from a year earlier, with the FY2025 full-year figure at $549.0 million, up 12.27% from the prior year.
• Non-Current Assets was $508.0 million for Q2 2026 at Indivior Pharmaceuticals, down from $530.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $549.0 million in Q4 2025, with the low at -$1.3 billion in Q4 2022.
• Average Non-Current Assets over 5 years is $311.7 million, with a median of $501.0 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 139.79% in 2023, then fell 2.4% in 2024.
• Over 5 years, Non-Current Assets stood at -$1.3 billion in 2022, then jumped by 139.79% to $501.0 million in 2023, then retreated by 2.4% to $489.0 million in 2024, then grew by 12.27% to $549.0 million in 2025, then slipped by 7.47% to $508.0 million in 2026.
• The last three Non-Current Assets figures came in at $508.0 million (Q2 2026), $530.0 million (Q1 2026), and $549.0 million (Q4 2025), per Business Quant data.